Daiichi Sankyo announced its first quarter fiscal year 2026 financial results, revealing a 21.1% year-over-year increase in global revenue to 574.7 billion yen ($3.9 billion). This growth was primarily attributed to robust sales of its global oncology products, particularly Enhertu and Datroway, and a positive foreign exchange effect from the depreciation of the Japanese yen, which contributed 41.9 billion yen ($284 million) to revenue.
Despite the strong revenue performance, operating profit for the quarter decreased by 12.0% year-over-year to 85.1 billion yen ($576 million). This decline was largely due to restructuring expenses within the EU Specialty Business Unit and increased selling, general, and administrative expenses, including higher profit-sharing with AstraZeneca. However, core operating profit, which excludes these non-core expenses, saw a 6.2% increase to 107.3 billion yen ($727 million), benefiting from a 9.7 billion yen ($66 million) positive foreign exchange impact.
Following these results, Daiichi Sankyo has revised its full fiscal year 2026 guidance upward. Global revenue is now projected to increase from 2.28 trillion yen ($15.4 billion) to 2.34 trillion yen ($15.8 billion), driven by anticipated stronger sales in the U.S. and continued favorable foreign exchange rates. Operating profit guidance has also been raised from 315.0 billion yen ($2.13 billion) to 320.0 billion yen ($2.16 billion). The company also secured key approvals in Q1 FY2026, including Enhertu in the U.S. and Europe for HER2-positive early breast cancer and Datroway in the U.S. for first-line treatment of triple-negative breast cancer.
